Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04649203
Other study ID # CTF-III-DM-2019
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 25, 2020
Est. completion date June 6, 2021

Study information

Verified date January 2023
Source POLYSAN Scientific & Technological Pharmaceutical Company
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

One of the most common complications of diabetes mellitus is diabetic polyneuropathy, which leads to disability and reduces quality of life. The toxic effects of high glucose concentrations contribute to the formation of ketoaldehyde free radicals, which, at an increased rate of their formation, leads to the development of oxidative stress in the nervous tissue. The planned study of the use of Cytoflavin® in diabetic polyneuropathy is substantiated by its antioxidant effect, which, by analogy with alpha-lipoic acid preparations, suggests its efficacy in the combined treatment of such patients. This clinical study is being conducted to assess the efficacy and safety of Cytoflavin® versus Placebo in diabetic polyneuropathy patients with type 2 diabetes. Study patients will receive study medication, 10 IV infusions followed by 75 days of oral intake. Clinical efficacy will be assessed by alleviation of symptoms (burning, numbness, pain and pricking), using the total symptoms score(TSS), after the completion of the treatment course.


Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date June 6, 2021
Est. primary completion date March 29, 2021
Accepts healthy volunteers No
Gender All
Age group 45 Years to 74 Years
Eligibility Inclusion Criteria: - Signed informed consent form; - Men and women aged 45 to 74 (inclusive); - Confirmed diagnosis of type 2 diabetes lasting for 1 year or more; - Permanent scheme of therapy (without changing doses and drugs) by oral hypoglycemic drugs and / or insulin, long-term or ultra-long (adjustment of insulin dose is possible within 10% from baseline dose) and / or agonists of glucagon-like peptide-1 receptors (GLP-1) for at least 12 weeks before screening; - HbA1c from 7.0 and not higher than 10.0%; - BMI 22-40 kg / m2; - Symptomatic distal sensorimotor diabetic polyneuropathy; - Baseline TSS (Total Syptom Score) ?5 points; - Score =2 by at least one of the TSS symptoms; - The severity of pain by the corresponding TSS subscale = 2; - NISLL (Neuropathy Impairment Score Low Limbs) = 2 points; - Patient consent to use adequate contraceptive methods for the entire study; - Consent to maintain a stable diet, exercise, therapy and diabetes control throughout the study; - Ability to comply with all protocol requirements. Exclusion Criteria: - Pregnant or lactating women, or women planning a pregnancy during a clinical trial; - Type 1 diabetes and other specific types of diabetes; - Acute metabolic complications of diabetes such as ketoacidosis or hyperosmolar state within 6 months prior to screening; - Therapy with short and ultra-short insulin within 3 months before screening; - Fasting plasma glucose at screening> 15 mmol / l; - The presence of severe complications of diabetes; - Epilepsy, epileptiform seizures, head trauma with loss of consciousness, tumor, inflammatory and demyelinating diseases of the central nervous system; - Diseases requiring prior or current treatment by systemic corticosteroid drugs, cytostatics or penicillamine;malignant neoplasms within the last 5 years (excluding basal cell carcinoma); - Cardiovascular diseases in the stage of decompensation at present or within 3 months before screening; - Uncontrolled arterial hypertension with systolic arterial pressure> 180 mm Hg and diastolic blood pressure> 110 mm Hg at screening; - Nephrotic syndrome, severe chronic renal failure or significant kidney disease with a level of glomerular filtration rate (GFR) <30 ml / min; - Active viral (hepatitis B and C) or cirrhotic liver disease; increased aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) 3 times from upper normal limit; increased total bilirubin 2 times from upper normal limit; - HIV; a severe infectious disease within 30 days before screening; - Anemia (hemoglobin = 105 g / l in women or = 115 g / l in men); acute blood loss or donation of at least one unit of blood (500 ml) or blood transfusion within the previous 12 weeks; - Drug or alcohol abuse; - Intake of Cytoflavin® for 3 months before screening; - Known allergies, hypersensitivity or contraindications to the drug Cytoflavin® or its components; - Intake of alpha-lipoic acid, thiamine derivatives, pyridoxine, cyanocobalamin (excluding multivitamins), antidepressants and derivatives of gabapentin within 3 months before screening; - Use of other investigational drugs within 3 months prior to screening; - Inability to read or write; unwillingness to understand and follow protocol procedures; non-compliance with the protocol requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
The study drug will be administered in two phases: intravenous infusion of study drug for 10 days followed by oral administration of study drug for 75 days. Thus, the total duration of the study therapy is 12 weeks.
Placebo
The placebo comparator will be administered in two phases: intravenous infusion of placebo solution for 10 days followed by oral administration of placebo pills for 75 days. Thus, the total duration of the study therapy is 12 weeks.

Locations

Country Name City State
Russian Federation City Clinical Hospital n.a. V.P.Demikhov Moscow
Russian Federation City Clinical Hospital n.a.M.E.Zhadkevitch Moscow
Russian Federation City Clinical Hospital #13 Avtozavodsky district Nizhny Novgorod
Russian Federation "Astarta" Ltd. Saint Petersburg
Russian Federation City General Hospital ?2 Saint Petersburg
Russian Federation City Outpatient Clinic #51 Saint Petersburg
Russian Federation I. P. Pavlov 1st St. Petersburg State Medical University Saint Petersburg
Russian Federation North-West State Medical University named after I.I. Mechnikov Saint Petersburg
Russian Federation Research Center for Eco-safety, Ltd. Saint Petersburg
Russian Federation "Consultative and diagnostic center with a polyclinic" of the Administrative Department of the President of the Russian Federation Saint-Petersburg
Russian Federation Almazov National Medical Research Centre Saint-Petersburg
Russian Federation City Outpatient Clinic #117 Saint-Petersburg
Russian Federation MEDICA Ltd. Saint-Petersburg
Russian Federation "Diabetes" medical center Samara
Russian Federation Saratov State Medical University n.a. V.I.Razumovsky Saratov
Russian Federation GBUZ YAO "Regional Clinical Hospital" Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
POLYSAN Scientific & Technological Pharmaceutical Company

Country where clinical trial is conducted

Russian Federation, 

References & Publications (1)

Kharitonova T, Shvarts YG, Verbovoy AF, Orlova NS, Puzyreva VP, Strokov IA. Efficacy and safety of the combined metabolic medication, containing inosine, nicotinamide, riboflavin and succinic acid, for the treatment of diabetic neuropathy: a multicenter r — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary TSS (Total Symptom Score) Change in total TSS score at Week 12 from baseline 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05683106 - Effects of Customized Silicone Digital Orthoses in People With Diabetic Neuropathy N/A
Withdrawn NCT04106050 - Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy Phase 1
Completed NCT04088929 - The Use of a Water Soluble Under the Tongue (Sublingual) CBD Tablet for Treating Pain Associated With Diabetic Peripheral Neuropathy Phase 2
Completed NCT01939366 - Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves Phase 2
Withdrawn NCT00815932 - The Effect of Transcranial Direct Current Stimulation (t-DCS) On the P300 Component of Event-Related Potentials in Patients With Chronic Neuropathic Pain Due To CRPS or Diabetic Neuropathy N/A
Completed NCT01926522 - Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients N/A
Not yet recruiting NCT01180608 - Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain N/A
Completed NCT00380913 - Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Diabetic Peripheral Neuropathy Phase 4
Completed NCT00760955 - Efficacy and Safety of TAK-583 in Subjects With Diabetic Peripheral Neuropathy Phase 2
Terminated NCT00756041 - Safety Study of TAK-128 in Subjects With Diabetic Peripheral Neuropathy Phase 2
Completed NCT05255497 - The Effect of Sensorial Biodex Balance Balance System Exercises in Diabetic Neuropathy N/A
Completed NCT06061237 - Effects of Aerobic Thai Dance in Patient With Diabetic Peripheral Neuropathy N/A
Terminated NCT02915263 - The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes Phase 2
Enrolling by invitation NCT05043636 - Diabetic Neuropathy Screening Study 1.1 + Substudy 1.2-1.3-1.4
Completed NCT06373809 - Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy Early Phase 1
Completed NCT05968131 - Comparative Effects of Proprioceptive Training and Routine Physical Therapy on Diabetic Peripheral Neuropathy N/A
Completed NCT00282685 - Safety and Feasibility Study of Autologous Progenitor Cell Transplantation in Diabetic Neuropathy Phase 1
Completed NCT00135109 - Trial to Assess the Efficacy and Safety of SPM 927 (200, 400, and 600mg/Day) in Subjects With Painful Distal Diabetic Neuropathy Phase 3
Completed NCT06292962 - Evaluating the Impact of Vagus Nerve Stimulation on Diabetic Peripheral Neuropathic Pain N/A
Completed NCT05058807 - Effects of Whole Body Vibration in Diabetic Peripheral Neuropathy . N/A